The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
Open accessAbstract
BACKGROUND Geographic atrophy is an advanced form of dry age-related macular degeneration that can lead to irreversible vision loss and high burden of disease. We aimed to assess efficacy and safety of avacincaptad pegol 2 mg in reducing geographic atrophy lesion growth. METHODS GATHER2 is a randomised, double-masked, sham-controlled, 24-month, phase 3 trial across 205 retina clinics, research hospitals, and academic institutions globally. To be eligible, patients had to be aged 50 years or older with non-centrepoint-involving geographic atrophy and best corrected visual acuity between 20/25 and 20/320 in the study eye. Eligible patients were randomly assigned (1:1) to monthly avacincaptad pegol 2 mg administered as a 100 μL intravitreal injection or sham for the first 12 months. Randomisation was performed using an interactive response technology system with stratification by factors known to be of prognostic importance in age-related macular degeneration. Patients, investigators, study centre staff, sponsor personnel, and data analysts were masked to treatment allocation. The primary endpoint was geographic atrophy lesion size measured by fundus autofluorescence at baseline, month 6, and month 12. Efficacy and safety analyses were done in the modified intention-to-treat and safety populations, respectively. This trial is registered with ClinicalTrials.gov, NCT04435366. FINDINGS Between June 22, 2020, and July 23, 2021, 1422 patients were screened for eligibility, of whom 448 were enrolled and randomly assigned to avacincaptad pegol 2 mg (n=225) or sham (n=223). One patient in the sham group did not receive study treatment and was excluded from analyses. There were 154 (68%) female patients and 71 (32%) male patients in the avacincaptad pegol 2 mg group, and 156 (70%) female patients and 66 (30%) male patients in the sham group. From baseline to month 12, the mean rate of square-root-transformed geographic atrophy area growth was 0·336 mm/year (SE 0·032) with avacincaptad pegol 2 mg and 0·392 mm/year (0·033) with sham, a difference in growth of 0·056 mm/year (95% CI 0·016-0·096; p=0·0064), representing a 14% difference between the avacincaptad pegol 2 mg group and the sham group. Ocular treatment-emergent adverse events in the study eye occurred in 110 (49%) patients in the avacincaptad pegol 2 mg group and 83 (37%) in the sham group. There were no endophthalmitis, intraocular inflammation, or ischaemic optic neuropathy events over 12 months. To month 12, macular neovascularisation in the study eye occurred in 15 (7%) patients in the avacincaptad pegol 2 mg group and nine (4%) in the sham group, with exudative macular neovascularisation occurring in 11 (5%) in the avacincaptad pegol 2 mg group and seven (3%) in the sham group. INTERPRETATION Monthly avacincaptad pegol 2 mg was well tolerated and showed significantly slower geographic atrophy growth over 12 months than sham treatment, suggesting that avacincaptad pegol might slow disease progression and potentially change the trajectory of disease for patients with geographic atrophy. FUNDING Iveric Bio, An Astellas Company.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Age-related macular degeneration
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C., Wong, W. T., & Chew, E. Y. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00265-2 · Cited by 978
Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data
Spaide, R. F., Jaffe, G. J., Sarraf, D., Freund, K. B., Sadda, S. R., Staurenghi, G., Waheed, N. K., Chakravarthy, U., Rosenfeld, P. J., Holz, F. G., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.11.004 · Cited by 824
Self-citationThe Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Fleckenstein, M., Mitchell, P., Freund, K. B., Sadda, S., Holz, F. G., Brittain, C., Henry, E. C., & Ferrara, D. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.038 · Cited by 561
Liao, D. S., Grossi, F. V., El Mehdi, D., Gerber, M. R., Brown, D. M., Heier, J. S., Wykoff, C. C., Singerman, L. J., Abraham, P., Grassmann, F., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.07.011 · Cited by 519
Self-citationC5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
Jaffe, G. J., Westby, K., Csaky, K. G., Monés, J., Pearlman, J. A., Patel, S. S., Joondeph, B. C., Randolph, J., Masonson, H., & Rezaei, K. A. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.08.027 · Cited by 469
Self-citationVEGF is major stimulator in model of choroidal neovascularization.
Kwak, N., Okamoto, N., Wood, J. M., & Campochiaro, P. A. (2000) · PubMed · Cited by 442
Holz, F. G., Strauss, E. C., Schmitz-Valckenberg, S., & van Lookeren Campagne, M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.023 · Cited by 402
Yehoshua, Z., Rosenfeld, P. J., Gregori, G., Feuer, W. J., Falcão, M., Lujan, B. J., & Puliafito, C. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.08.018 · Cited by 292
Self-citationCoulthard, L. G., & Woodruff, T. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403068 · Cited by 285
Cited by
Age-Related Macular Degeneration: A Review
Fleckenstein, M., Schmitz-Valckenberg, S., & Chakravarthy, U. (2024) · JAMA · doi:10.1001/jama.2023.26074 · Cited by 549
Metadata
- Authors
- Khanani, A. M., Patel, S. S., Staurenghi, G., Tadayoni, R., Danzig, C. J., Eichenbaum, D. A., Hsu, J., Wykoff, C. C., Heier, J. S., Lally, D. R., Monés, J., Nielsen, J. S., Sheth, V. S., Kaiser, P. K., Clark, J., Zhu, L., Patel, H., Tang, J., Desai, D., Jaffe, G. J., Alezzandrini, A., Francone, A. A., Bafalluy, J., Bainttein, S., Luna Pinto, J., Saravia, M., Vidosevich, M., Zeolite, C., Furno Sola, F., Chang, A., Cornish, E. E. G., Nguyen, T., Findl, O., Haas, A., Kralinger, M., Sacu, S., Postelmans, L. D., Farah, M., Maia, M., Nehemy, M., Ali, F., Brent, M., Dollin, M., Gonder, J., Kherani, A., Merkur, A., Tuli, R., Lopera, M. M., Rodriguez, F., Bradvica, M., Ernest, J., Kalijurand, K., Noor, K., Cohen, Y., Creuzot-Garcher, C., De Bats, F., Devin, F., Français-Maury, C., Kodjikian, L., Korobelnik, J. F., Le Mer, Y., Quaranta El Maftouhi, M., Razavi, S., Souied, E., Tadayoni, R., Weber, M., Eter, N., Feltgen, N., Grisanti, S., Walter, P., Liegl, R., Lorenz, K., Spital, G., Priglinger, S., Spitzer, M., Volker, M., Krohne, T., Jochmann, C., Lohmann, C. P., Framme, C., Kerenyi, A., Papp, A., Seres, A., Toth-Molnar, E., Tsorbatzoglou, A., Vajas, A., Varsanyi, B., Vogt, G., Bar, A., Eting, E., Hauser, D., Levy, J., Mathalone, N., Morori-Katz, H., Rosenblatt, I., Soudry-Zayit, S., Trivizky, O., Bandello, F., Ciardella, A. P., Figus, M., Giansanti, F., Lanzetta, P., Mariotti, C., Mastropasqua, L., Midena, E., Parmeggiani, F., Ricci, F., Simonelli, F., Staurenghi, G., Viola, F., Varano, M., Laganovska, G., Cisiecki, S., Jedrzejewski, W., Kaluzny, J., Misiuk-Hojło, M., Abengoechea, S., Iribarren, J. A., Ascaso, F. J., Cubero, J. M., Gallego-Pinazo, R., Gomez-Ulla De Irazazabal, F., Mestre, I. J., Mones I Carilla, J. M., Montero Moreno, J., María Ruiz Moreno, J., Sararols Ramsay, L., Garcia Layana, A., Downey, L., Abraham, P., Alfaro, D. V., Bagheri, N., Barbazetto, I., Benevento, J., Bernstein, P., Bertolucci, G., Bhavsar, A., Bridges, W., Brooks, Jr., Brown, J., Brucker, A., Calvo, C. M., Capone, A., Carlson, J., Chan, C., Chang, E., Chan-Kai, B., Chaudhry, N., Chen, S., Csaky, K., Cummings, H., Danzig, C., Dessouki, A., Dyer, D., Eaton, A., Eichenbaum, D., Faber, D., Feldman, R., Finnen, N., Freeman, W., Frenkel, R., Gonzales, C., Gonzalez, V., Gross, J., Gupta, S., Hall, E., Han, M.-K., Heier, J., Hershberger, V., Higgins, P., Hsu, J., Ip, M., Jablon, E., Jewart, B., John, V., Jonisch, J., Joondeph, B., Kay, C., Khanani, A., Kokame, G. T., Kwun, R., Lai, M., Lally, D., Laud, K., Lavina, A., Lee, M., Lin, P., Lin, H., Manoharan, N., Marcus, D., Martidis, A., McCabe, F., Nielsen, J., Osher, J., Palmer, J., Patel, S., Pearlman, J., Perkins, S., Pirouz, A., Qureshi, J., Randolph, J., Piri, N., Rosenfeld, P., Saperstein, D., Scartozzi, R., Schwartz, S., Sharma, A., Sharma, A., Sheth, V., Singer, M., Spinak, D., Suan, E., Tabandeh, H., Tabassian, A., Uchiyama, E., Varenhorst, M., Wagner, A., Warrow, D., Wells, III, Wong, R., Wong, K., Wykoff, C., Xavier, S., & Ysasaga, E.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 402
- Issue
- 10411
- Pages
- 1449-1458
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4386552811
- Cited by
- 366
- References
- 25
- FWCI
- 75.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)01583-0
- The paper
- Khanani, A. M., Patel, S. S., Staurenghi, G., Tadayoni, R., Danzig, C. J., Eichenbaum, D. A., Hsu, J., Wykoff, C. C., Heier, J. S., Lally, D. R., Monés, J., Nielsen, J. S., Sheth, V. S., Kaiser, P. K., Clark, J., Zhu, L., Patel, H., Tang, J., Desai, D., . . . Ysasaga, E. (2023). Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)01583-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.